<DOC>
	<DOCNO>NCT01926158</DOCNO>
	<brief_summary>This randomize clinical trial evaluate efficacy antiresorptive osteoporosis drug ( denosumab ) prevention periprosthetic bone loss promotion implant osseointegration ( bone bonding ) postmenopausal woman total hip replacement . The patient low bone mineral density ( BMD ) normal BMD analyze separate group . The investigator assume denosumab prevents periprosthetic bone loss enhance bone bond hip stem woman osteoporosis .</brief_summary>
	<brief_title>Denosumab Enhancement Bone Bonding Hip Prosthesis Postmenopausal Women</brief_title>
	<detailed_description>This randomize , double-blind placebo-controlled trial evaluate efficacy denosumab biologic incorporation cementless hip prosthesis . The study population consist sixty-eight postmenopausal female patient , schedule cementless total hip replacement ( THA ) primary hip osteoarthritis . The patient stratify base preoperative DXA screen systemic bone mineral density ( BMD ) . Patients normal BMD patient low BMD ( T-score le -2 ) randomize within stratum . The patient randomly assign receive subcutaneous injection denosumab 60 mg placebo four week surgery 22 week surgery . The primary hypothesis denosumab effective preventing periprosthetic bone loss proximal femur measure DXA . The secondary hypothesis denosumab effective enhancement bone bonding ( osseointegration ) cementless femoral stem , measure model-based radiostereometric analysis .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Postmenopausal woman , age : ≥ 60 year ≤ 85 year randomization Degenerative primary hip OA indication hip replacement Signed informed consent Presence severe osteoporosis ( Tscore le 4.0 previous fracture ) Presence Dorr Ctype geometric change proximal femur Evidence secondary osteoporosis Clinical laboratory evidence hepatic disease Laboratory evidence hypocalcaemia Vitamin D deficiency ( serum 25OH ( D ) &lt; 12 ng/mL ) Disorders parathyroid function Uncontrolled hyperthyroidism hypothyroidism History malignancy , radiotherapy chemotherapy malignancy ( except basal cell carcinoma skin ) within last 5 year History osteonecrosis jaw History recent tooth extraction dental surgery and/or invasive dental work plan next 2 year Severe asthma chronic obstructive pulmonary disease History solid organ bone marrow transplant Use within 12 month drug affect bone metabolism antosteoporotic agent ( include SERMS ) , estrogens , testosterone , antiepileptic : Cumulative dose 500 mg prednisone equivalent within last 6 month Ever use oral iv bisphosphonates Ever use strontium ranelate fluoride Use follow medication : chronic systemic ketoconazole androgen ACTH cinacalcet aluminum lithium protease inhibitor gonadotropinreleasing hormone agonist Rheumatoid arthritis inflammatory arthritis History skeletal disorder , Paget 's disease osteomalacia Alcohol abuse General Mental , neurological condition may affect ability perform functional clinical assessment require protocol Subjects know sensitivity intolerance product administer ( calcium Dvitamin supplement , denosumab ) Subject available protocolrequired study visit , best subject 's investigator 's knowledge Any condition , judgement investigator , may compromise ability subject give write informed consent and/or comply require study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Denosumab</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Hip replacement</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Radiostereometric analysis ( RSA )</keyword>
	<keyword>Dual energy X-ray absorptiometry ( DXA )</keyword>
</DOC>